Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $6.33

Shares of Precigen, Inc. (NASDAQ:PGEN) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $6.33.

A number of research analysts have issued reports on PGEN shares. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Precigen in a research report on Friday, November 15th.

Precigen Trading Down 4.2 %

Shares of NASDAQ PGEN opened at $1.13 on Monday. The company has a market capitalization of $330.94 million, a P/E ratio of -2.05 and a beta of 1.65. The stock has a 50 day moving average of $0.92 and a 200-day moving average of $1.06. Precigen has a 12 month low of $0.65 and a 12 month high of $1.93.

Institutional Trading of Precigen

Large investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of Precigen by 1.0% in the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after purchasing an additional 29,253 shares during the period. Iridian Asset Management LLC CT increased its position in Precigen by 82.5% during the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after acquiring an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC lifted its stake in Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares during the last quarter. Stifel Financial Corp lifted its stake in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 15,680 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Precigen by 190.4% during the third quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 124,141 shares during the period. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.